Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026CancersOpen Access

FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

GSGiorgia SilvestriniSTSerena TravagliniLGLuca Guarnera

Discussion

Loading...

Member takes

Overview

Review discusses FLT3-ITD mutations' role in measurable residual disease, influencing therapy decisions in acute myeloid leukemia.

Key Points

  • This review aims to examine the implications of FLT3-ITD mutations in measurable residual disease for acute myeloid leukemia treatment strategies.
  • Review of current literature on FLT3-ITD mutations in AML
  • Discussion on next-generation sequencing techniques for MRD detection
  • Evaluation of FLT3-ITD's role in risk stratification and treatment decisions
  • FLT3-ITD mutations are found in 20-25% of AML cases and indicate high relapse risk.
  • Ultra-high sensitivity next-generation sequencing enhances FLT3-ITD MRD detection, allowing monitoring of very low variant allele frequencies.
  • FLT3-ITD MRD monitoring is emerging as a significant prognostic tool for tailoring post-remission therapies.

Cite This Study

Silvestrini et al. (2026) studied this question.

synapsesocial.com/papers/6a7d76aa2b0e0cff3f6403a2https://doi.org/10.3390/cancers18162586
View Full Paper
Ask AI
Bookmark
Share